Note: Descriptions are shown in the official language in which they were submitted.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
1
GLYCOPEPTIDE COMPOSITIONS
Background
Vancomycin is a tricyclic glycopeptide antibiotic derived from Amycolatopsis
orientalis (formerly Nocardia orientalis).
In pharmaceutical use, it is usually administered as the hydrochloride salt,
Vancomycin hydrochloride. This salt has previously been supplied for oral and
parenteral use as a dry solid or as a frozen liquid preparation. Heretofore,
liquid
formulations of Vancomycin hydrochloride have been impractical as
pharmaceutical
preparations because of the limited stability of the Vancomycin hydrochloride
in the
aqueous solution suitable for parenteral use. Similar limitations have been
observed
for liquid solutions made from glycopeptide antibiotics related to Vancomycin.
Vancomycin hydrochloride is indicated for the treatment of serious or severe
infections caused by susceptible strains of methicillin-resistant (beta-lactam-
resistant) staphylococci. It is indicated for penicillin-allergic patients,
for patients
who cannot receive or who have failed to respond to other drugs, including the
penicillins or cephalosporins, and for infections caused by vancomycin-
susceptible
organisms that are resistant to other antimicrobial drugs. Related
glycopeptide
antibiotics, such as Teicoplanin and Telavancin, are also used for the
treatment of
multi-drug resistant gram-positive bacterial infections.
Many attempts have been performed to stabilize Vancomycin and related
glycopeptide antibiotics in liquid preparations.
US4670258 disclosed protection of Vancomycin against thermal degradation by
mixing certain acetylated dipeptides or tripeptides with Vancomycin in
solution in a
narrow molar ratio of 1 to 2 moles of peptide to Vancomycin. The use of
similarly
derivatized single amino acids was not suggested or investigated. The
acetylated
peptides studied in this patent are designed to mimic the binding of
Vancomycin to
its target in vivo, and the inventors believed that this prevented
inactivation of
Vancomycin by blocking formation of an isoaspartate from the Vancomycin
backbone asparagine residue. However, stability of the Vancomycin in solution
was
only measured up to 66 hours at room temperature and at 80 degrees Celsius.
W09719690 disclosed stable solutions of Vancomycin HC1 comprising 0.5-30 %
vol/vol ethanol. These solutions are claimed to be particularly useful for
storage in a
liquid state not requiring either freezing or freeze-drying in order to
maintain
stability.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
2
JP11080021 mentioned Vancomycin injection solutions showing storage stability
comprising water, Vancomycin and 0.1-10 wt % amino acids (i.e. Glycine) to
inhibit color formation.
US8778873 discloses a stability study for a combination of Ceftriazone and
Vancomycin at pH 8.8. L-arginine, L-Lysine and L-Histidine are claimed as
"compatibility/stabilizing agent".
W02014026052 disclosed that a D-AA mixture enhanced the effect of Rifampin,
Clindamycin, and Vancomycin resulting in significant reductions of bacterial
CFUs
within the biofilms.
US20140260098A1 mentioned that stabilizers and/or solubilizers are added to
the Vancomycin hydrochloride solution to get a mixture solution of Vancomycin
hydrochloride and excipients. The stabilizers may comprise saccharides and/or
polyols. The formulation with trehalose and tween has the best product
stability.
W02014085526 discloses stabilized lipid-based Vancomycin compositions
wherein amino acids or derivatives thereof stabilize Vancomycin.
Several groups have studied the interactions of Vancomycin and related
glycopeptide antibiotics with certain ligands in order to better understand
the
interactions of the antibiotic molecules targets in vivo.
For example, McPhail and Cooper, J. Chem. Soc, Faraday Trans., vol 93. no 13,
1997, compared the thermodynamics of dissociation of Vancomycin and Ristocetin
dimers in the presence and absence of weakly binding (acetate, N-acetyl-D-Ala)
and
strongly binding (Na,N8-diacetyl-Lys-D-Ala-D-Ala) ligands over a range of
conditions.
Loll et al, Chemistry and Biology, vol. 5 no. 5, 1998 disclosed the crystal
structure of Vancomycin in complex with N-acetyl-D-Alanine (AcDA), which
demonstrates that Vancomycin forms ligand-mediated face-to-face dimers as well
as
the ligand-independent back-to-back dimers previously observed by nuclear
magnetic resonance.
Loll et al, Journal of Medicinal Chemistry, 1999, Vol. 42, No. 22 4715, 1999
showed how N-acetyl-D-Alanine and N-acetyl-Glycine binds to Vancomycin.
Still other groups have studied the interaction of peptide and single amino
acid
ligands to Vancomycin in terms of molecular rigidity and conformation changes
induced in Vancomycin by such binding interactions. These groups showed that
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
3
peptide ligands interact with the molecular backbone of Vancomycin and related
glycopeptide antibiotics in multiple places, while single amino acid ligands
such as
N-acetyl-D-Alanine interact in a more limited fashion. See, e.g., Brown JP et
al.
(1975), Mol. Pharmacol. 11:126-132; Harris CM et al. (1984), J. Antibiotics
38(1):
51-57; Williams DH et al. (1993), Proc. Nat. Acad. Sci. US 90:1172-1178;
Pearce
CM et al. (1995), J. Chem. Sci. Perkins Trans. 2: 159-162; and Rao J et al.
(1999),
Chem. & Biol. 6: 353-359. Harris CM et al. suggest that the relative
structural
rigidity conveyed to the Vancomycin molecule on binding with di- and tri-
peptides
in solution blocked rearrangement of the Vancomycin backbone asparagine to
isoaspartate via a cyclic imide intermediate. This is consistent with the
observation
of the inventors in US4670258 discussed above. However, although single amino
acid ligands such as N-acetyl-D-Alanine may be involved in glycopeptide
antibiotic
dimerization in solution under certain conditions, it is not clear that such
ligands
confer similar structural rigidity in a complex with antibiotics such as
Vancomycin
as do the di- and tri-peptide ligands. Moreover, these studies did not
investigate or
discuss the long-term stability of Vancomycin and related glycopeptide
antibiotics
in solutions for pharmaceutical use.
Raverdy et al (J Antimicrob Chemother 2013; 68: 1179-1182), observed the
stability of an intravenous solution of 10 g/L Vancomycin in 5% glucose for up
to
48 hours under conditions that simulated delivery of the solution to a
patient, and
for up to 72 hours at 50 degrees Celsius. The study also examined the
solution's
compatibility with various substances co-administered through a Y-connector,
for a
contact time of one hour at room temperature. The authors concluded that,
under the
observed conditions and times, the Vancomycin was stable and that N-acetyl-
Cysteine (used as an antioxidant in cases of Paracetamol intoxication) and
amino
acid solutions (used for parenteral nutrition) did not cause alteration of
Vancomycin
when co-administered. However, the conditions and components necessary for
long-
term stability of Vancomycin solutions were not investigated or discussed.
Thus, there remains a need for solutions of Vancomycin and related
glycopeptides which possess long-term stability under conditions of normal use
and
storage, and which remain suitable for administration to a subject throughout
their
stability period.
Summary of the Invention
The present invention concerns stabilized pharmaceutical compositions
comprising glycopeptide antibiotics. In preferred embodiments, present
invention
concerns stabilized pharmaceutical compositions comprising Vancomycin.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
4
The present invention provides glycopeptide antibiotic compositions comprising
an N-acetyl-D-amino acid or N-acetyl-Glycine.
The present invention provides glycopeptide antibiotic compositions comprising
an N-acetyl-D-amino acid or N-acetyl-Glycine for use as a medicament.
The present invention provides glycopeptide antibiotic compositions comprising
an N-acetyl-D-amino acid or N-acetyl-Glycine for use in treatment of bacterial
infections.
The present invention provides glycopeptide antibiotic compositions comprising
N-acetyl-D-Alanine or N-acetyl-Glycine.
The present invention provides glycopeptide antibiotic compositions comprising
N-acetyl-D-Alanine or N-acetyl-Glycine for use as a medicament.
The present invention provides glycopeptide antibiotic compositions comprising
N-acetyl-D-Alanine or N-acetyl-Glycine for use in treatment of bacterial
infections.
In one embodiment of the present invention, the compositions are aqueous.
In one embodiment of the present invention, the compositions are aqueous and
have a pH of about 2-7.
In one embodiment of the present invention, the compositions are aqueous and
have a pH of about 3-6.
In one embodiment of the present invention, the compositions are aqueous and
have a pH of about 4.0-5.5.
In one embodiment of the present invention, the compositions are aqueous and
have a pH of about 4.5-5.5.
In one embodiment of the present invention, the compositions further comprise
an amino acid and/or an organic solvent.
In one embodiment of the present invention, the compositions further comprise
an amino acid selected from Glycine, Alanine, Serine, Leucine, Valine, Lysine,
Arginine and Ornithine.
In one embodiment of the present invention, the compositions further comprise
an amino acid selected from D-Alanine, D-Serine, D-Leucine, D-Valine, L-
Lysine,
D-Lysine, L-Ornithine, D-Ornithine or L-Arginine.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
In one embodiment of the present invention, the compositions further comprise
an amino acid selected from D-Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine,
L-Ornithine, D-Ornithine or L-Arginine.
5
The compositions according to the present invention are suitable for storage
in
liquid state, thus providing vials, syringes and "ready to use" IV containers,
as are
known in the art, comprising the stabilized Vancomycin compositions. When
administering these to patients, there is no need for the step of
reconstituting a
lyophilized Vancomycin powder; however, the content of vials and syringes
could
be further diluted to target concentration prior to administration. Suitable
diluents
for solutions of the invention include any known diluent acceptable for
pharmaceutical use (e.g., intravenous administration); for example, water,
physiological saline, 5% dextrose solution, lactated Ringer's solution or
combinations thereof.
The present invention further provides a method for stabilizing glycopeptide
antibiotics which involves addition of N-acetyl-D-amino acids to a solution
comprising a glycopeptide antibiotic or addition of a glycopeptide antibiotic
to a
solution comprising N-acetyl-D-amino acids.
In one embodiment, at least one additional amino acid is also added and/or at
least one pharmaceutically acceptable organic solvent is added.
The present invention provides a method for stabilizing a glycopeptide
antibiotic
which involves addition of N-acetyl-D-Alanine to a solution comprising a
glycopeptide antibiotic or addition of a glycopeptide antibiotic to a solution
comprising N-acetyl-D-Alanine.
In one embodiment, at least one additional amino acid is also added and/or at
least one pharmaceutically acceptable organic solvent is added.
The present invention provides solutions comprising about 0.1-1% w/V of
Vancomycin and N-acetyl-D-Alanine, wherein the solutions have a pH of about 4-
6.
In one embodiment, the solutions further comprise an amino acid selected from
D-Alanine, D-Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Ornithine, D-
Ornithine or L-Arginine.
In another embodiment, the solutions further comprise L-Lysine.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
6
In another embodiment, the solutions further comprise L-Lysine and have a pH
of about 4.5-5.5.
In another embodiment, the solutions further comprise L-Lysine and have a pH
of about 4.5-5.5, wherein the molar ratio of glycopeptide antibiotic to L-
Lysine is
about 1:5-1:30.
In another embodiment, the solutions further comprise L-Lysine and have a pH
of about 4.5-5.5, wherein the molar ratio of glycopeptide antibiotic to N-
acetyl-D-
Alanine is about 1:5-1:40 and wherein the molar ratio of glycopeptide
antibiotic to
L- Lysine is about 1:5-1:30.
The present invention provides solutions comprising about 3-10% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine, wherein the solutions have a
pH of
about 4-6.
The present invention provides solutions comprising about 0.1-1% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine, wherein the solutions have a
pH of
about 4-6.
The present invention provides solutions comprising about 1-10% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine, wherein the solutions have a
pH of
about 4-6.
In one embodiment, the solutions further comprise an amino acid selected from
D-Alanine, D-Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Ornithine, D-
Ornithine or L-Arginine.
In another embodiment, the solutions further comprise L-Lysine.
In another embodiment, the solutions further comprise L-Lysine and have a pH
of about 4.5-5.5.
In another embodiment, the solutions further comprise L-Lysine and have a pH
of about 4.5-5.5, wherein the molar ratio of glycopeptide antibiotic to L-
Lysine is
about 1:0.5-1:4.
In another embodiment, the solutions further comprise L-Lysine and have a pH
of about 4.5-5.5, wherein the molar ratio of glycopeptide antibiotic to N-
acetyl-D-
Alanine is about 1:1-1:4 and wherein the molar ratio of glycopeptide
antibiotic to L-
Lysine is about 1:0.5-1:4.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
7
The present invention provides aqueous solutions comprising about 0.5% w/V of
glycopeptide antibiotic and L-Lysine and N-acetyl-D-Alanine in a molar ratio
of
about 1:20:30, wherein the solutions have a pH of about 4.5-5.5.
The present invention provides aqueous solutions comprising about 5% w/V of
glycopeptide antibiotic and L-Lysine and N-acetyl-D-Alanine in a molar ratio
of
about 1:2:2, wherein the solutions have a pH of about 4.5-5.5.
Brief Description of the Drawing
Figure 1 is a representation of the molecular structures of Vancomycin,
Teicoplanin, Telavancin, Dalbavancin and Oritavancin as disclosed by Kang and
Park, Journal of Bacteriology and Virology 2015 vol. 45 no. 2 pages 67-78.
Detailed Description
Vancomycin is a tricyclic glycopeptide antibiotic. Its structure is
represented in
Formula 1. Its purity in the formulation can be assessed by the content of
Vancomycin B.
Mir 0100.it
r r
A " -.../H
--\:,
a. a
..-- = .
0 0
1,-
g . 1 "
--:,
--- )
1
..,..... I.
..........(X--
Formula 1.
"Vancomycin" as used herein means the compound represented in Formula 1 and
also pharmaceutically acceptable salts thereof, for example Vancomycin
Hydrochloride.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
8
Aqueous compositions comprising "Vancomycin HC1" is meant to cover, but not
meant to be limited to, solutions made by dissolving Vancomycin HC1 or by
addition of equimolar amounts of HC1 to Vancomycin base.
Vancomycin degrades into the following main degradation impurities: DAMS
(Des-(amido)-succinimido-Vancomycin B), which then converts to Des-(amido)-
isoaspartate-Vancomycin B minor/major (CDP1-m/M). The impurities Des-(amido)-
isoaspartate-Vancomycin B minor/major are quantified as one impurity named
CDP1 .
Structures of these two impurities are shown below as Formulas 2, 3a and 3b.
HQ
Re er
cm
fterf"
Istl \
=
i .
0 .
ty.
Formula 2. DAmS (Des-(amido)-succinimido-VancomycinB )
I"
04r,.,), r)::::(z.04... Illcic.
11 H
H4 a
I
0 ...,..
Formula 3a. CDP1 minor
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
9
4...., "='o..
V, es
6_.....z. ..../.
-.-C
- -4,
---.
Hqp..., 01 .. * =
, jtAl i
O MI
. 4. 0,11 ett, 60
li
il
4:
Formula 3b. CDP1 major
Other glycopeptide antibiotics which are related to Vancomycin are also within
the scope of the invention. As used herein, "glycopeptide antibiotic" means
molecules which contain a heptapeptide structure providing specific affinity
for the
D-alanyl-D-Alanine terminus of the peptidoglycan pentapeptide including, for
example, Vancomycin, Telavancin, Oritavancin, Teicoplanin and Dalbavancin (See
Parenti & Cavalleri, Journal of Antibiotics, December 1989 page 1882).
Structures
for some of these molecules are shown in Figure 1, which is adapted from Kang
and
Park, Journal of Bacteriology and Virology, 2015 vol. 45 no. 2 pages 67-78.
A "composition" is any mixture comprising more than one compound, for
example a mixture of two active ingredients or a mixture of an active
pharmaceutical ingredient and one or more pharmaceutical excipients. The
"compositions" according to the present invention include, but are not limited
to,
bulk solutions, solutions made by dissolving a lyophilized powder and
pharmaceutical solutions.
A "pharmaceutical composition" is any composition suitable and intended for in
vivo use, for example administration to a patient or a subject. As used
herein, the
terms "patient" and "subject" are interchangeable, and refer to any human or
animal
individual who is receiving a composition of the invention.
An "aqueous pharmaceutical composition" is a solution suitable and intended
for
in vivo use, for example administration to a patient, either directly or after
dilution
with a suitable diluent.
The term "amino acid" means any amino acid, including, but not limited to the
20 amino acids naturally occurring in peptides in both D and L-form and is
also
meant to cover any salt thereof, especially pharmaceutically acceptable salts.
For
example, the term "amino acid" includes Alanine, Arginine, Asparagine,
Aspartic
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
acid, Cysteine, Glutamic acid, Glutamine, Glycine, Histidine, Isoleucine,
Leucine,
Lysine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan,
Tyrosine, Valine and Ornithine, and any conformations thereof.
5 Thus the term "amino acid" includes L-Alanine, L-Arginine, L-Asparagine,
L-
Aspartic acid, L-Cysteine, L-Glutamic acid, L-Glutamine, L-Histidine, L-
Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Phenylalanine, L-Proline, L-
Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine and L-Ornithine.
10 Thus included is D-Alanine, D-Arginine, D-Asparagine, D-Aspartic acid, D-
Cysteine, D-Glutamic acid, D-Glutamine, D-Histidine, D-Isoleucine, D-Leucine,
D-
Lysine, D-Methionine, D-Phenylalanine, D-Proline, D-Serine, D-Threonine, D-
Tryptophan, D-Tyrosine, D-Valine and D-Ornithine.
"N-acetyl-Glycine" is a compound represented by the following structure:
o
H --- 0
H H
,Ny
H
H
o
or the compound as indicated by the CAS registry number 543-24-8.
It can exist as an acid or in deprotonated form. The term "N-acetyl-Glycine"
is also
meant to cover any salt thereof, especially pharmaceutically acceptable salts.
"N-acetyl-D-Alanine" is a compound which could be represented by the
following structure:
o H
R
H 0 H
ti H
H --- N esH
...
or the compound as indicated by the CAS registry number: 19436-52-3.
It can exist as an acid or in deprotonated form. The term "N-acetyl-D-Alanine"
is
also meant to cover any salt thereof, especially pharmaceutically acceptable
salts.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
11
"N-acetyl-D-amino acids" are compounds represented by the following structure
0
R1
H _______________________________ 0 j-Ir
H H
H N H
0
Formula 4
wherein R1 is a side chain of a-amino acids. Examples of such side chains
include -
CH3, -CH2OH and -CH(CH3)2 which are the side chains of Alanine, Serine and
Valine, respectively. The term "N-acetyl-D-amino acids" is also meant to cover
any
salt thereof, especially pharmaceutically acceptable salts.
"N-modified-D-amino acids" are compounds represented by the following
structure
o
R1
H - 0
H N R2
0
Formula 5
in which R1 is selected from -CH3, -CH2OH, -CH(CH3)2,
and R2 is selected from -H, -CH3, -CH2CH3
The term "N-modified-D-amino acids" is meant to cover salts (including
pharmaceutically-acceptable salts) thereof.
"pH" is the conventional measurement unit of hydrogen ion activity in a
solution
at 25 C unless another temperature is specified.
"pH of 3-6" is meant to include any pH value from 3-6 including pH 3 and
including pH 6 and any pH value in between 3 and 6.
"pH of 4-5.5" is meant to include any pH value from 4-5.5 including pH 4 and
including pH 5.5 and any pH value in between 4 and 5.5.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
12
The pH of the Vancomycin compositions according to the present invention is
affected by the concentration of each of the ingredients. The pH of the
Vancomycin
solutions according to the present invention can be adjusted in any suitable
manner,
e.g. by addition of aqueous hydrochloric acid solutions or aqueous sodium
hydroxide solutions. Such solutions can be diluted or concentrated. Thus,
suitable
pH adjusting agents include, but are not limited to 0.01 M HC1, 0.1 M HC1, 1 M
HC1, 2 M HC1, 3 M HC1, 4 M HC1, 5 M HC1, 6 M HC1, 0.01 M NaOH, 0.1 M
NaOH, 1 M NaOH, 2 M NaOH, 3 M NaOH, 4 M NaOH, 5 M NaOH and 6 M
NaOH. Thus, suitable pH adjusting agents include, but are not limited to 0.01-
6 M
HC1 and 0.01-6 M NaOH.
"Ultrapure water" means substantially pure water, e.g. water purified by
distillation or a purification process that is equivalent or superior to
distillation in
the removal of chemicals.
"Aqueous composition" means any solution in which water is the main solvent
(equal or above 50% V/V). Aqueous solutions include, but are not limited to
solutions comprising about 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98% or 99%
V/V water. The aqueous solutions can comprise a pharmaceutically acceptable
organic solvent like ethanol, polyethylene glycols (PEG 200, PEG 300, PEG 400,
PEG 600, PEG 4000 etc.). The aqueous solutions can comprise about 50% V/V or
less of a pharmaceutically acceptable organic solvent like ethanol, PEG 300,
PEG
400 etc.
"Bulk solution" is any solution suitable for lyophilization or for filling
into vials,
syringes or infusion containers (e.g., bottles or IV bags).
Glycopeptide antibiotic compositions according to the present invention can
thus
be in a liquid state; e.g., aqueous solutions with water as the only solvent
or
aqueous solutions further comprising an organic solvent (e.g., addition of
about 2-
50% V/V organic solvent, addition of about 2-40% V/V organic solvent, about 5-
40% V/V of organic solvent, about 10-30% V/V of organic solvent etc.).
Suitable organic solvents for the stabilized glycopeptide antibiotic
compositions
according to the present invention include any pharmaceutically acceptable
solvent
able to increase the solubility of the amino acids in the glycopeptide
antibiotic
solution. They include, but are not limited to, ethanol and polyethylene
glycols
(PEG 200, PEG 300, PEG 400, PEG 600, PEG 4000 etc.)
According to a preferred embodiment of the present invention, the glycopeptide
antibiotic solutions comprise about 5-30% V/V of ethanol. According to another
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
13
preferred embodiment of the present invention, glycopeptide antibiotic
solutions
comprise about 10% V/V of ethanol.
According to another preferred embodiment of the present invention, the
glycopeptide antibiotic solutions comprise about 50-60% V/V of polyethylene
glycol. According to a preferred embodiment of the present invention, the
glycopeptide antibiotic solutions comprise about 50-60% V/V of PEG 400.
According to a preferred embodiment of the present invention, the glycopeptide
antibiotic solutions comprise about 50-60% V/V of PEG 300. According to a
preferred embodiment of the present invention, glycopeptide antibiotic
solutions
comprise about 55% V/V of PEG 400.
In a preferred embodiment, the solutions of the invention comprise Vancomycin.
The present invention thus provides stable or stabilized glycopeptide
antibiotic
solutions, for example Vancomycin solutions. The stability of a glycopeptide
antibiotic solution according to the invention can be determined by measuring
the
amount of glycopeptide antibiotic, for example Vancomycin, remaining in a
solution of the invention after a predetermined time period, preferably
expressed as
a percentage, for example as a peak-area percentage of a chromatogram as
described
in more detail below. For example, a stable or stabilized solution according
to the
invention can be one which has at least about 85%, 86%, 87%, 88%, 89%, 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 100% of glycopeptide
antibiotic, for example Vancomycin, remaining after a predetermined time
period.
For example, the predetermined time period could be 18 months from the
manufacture date. The predetermined antibiotic amount or predetermined
antibiotic
purity could be any value as required according to pharmaceutical guidelines
or
pharmaceutical authorities, like a given chromatographic purity of the active
ingredient as measured according to the European Pharmacopoeia or USP.
Alternatively, the amount of glycopeptide antibiotic to glycopeptide
antibiotic
breakdown products, for example Vancomycin to Vancomycin breakdown products,
in the solution after a predetermined time period can be related to each other
to
express solution stability, preferably as a percentage of glycopeptide
antibiotic
remaining or of glycopeptide antibiotic impurities formed. For example, a
stable or
stabilized solution according to the invention can be one which has at least
about
85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99%, 99.5% or 100% of glycopeptide antibiotic, for example Vancomycin
remaining after a predetermined time period.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
14
Stability of the present solutions can also be expressed as the amount of
glycopeptide antibiotic, for example Vancomycin, impurities present after a
predetermined time period. For example, a stable or stabilized solution
according to
the invention can be one which has no more than about 15%, 14%, 13%, 12%, 11%,
10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or 0.5% of impurities present after a
predetermined time period.
It is not necessary to measure all types of glycopeptide antibiotic breakdown
products present, for example Vancomycin breakdown products present. It is
therefore contemplated by the present invention, in an exemplary embodiment,
that
stability of the present solutions can be determined by measuring the amount
of
DAMS (Formula 2) in the sample after a predetermined time period, and
expressing
that stability, for example, as a percentage of Vancomycin remaining or of
DAMS
present. Likewise, it is contemplated by the present invention that stability
of the
present solutions can be determined by measuring the amount of CDP1-m/M
(Formulas 3a and 3b) in the sample after a predetermined time period, and
expressing that stability, for example, as a percentage of Vancomycin
remaining or
of DAMS and/or CDP1-m/M present. The concentration of the glycopeptide
antibiotic or glycopeptide antibiotic impurities, for example Vancomycin or
Vancomycin impurities, in the present solutions can be measured by any
suitable
techniques, and expressed in any convenient units (i.e., chromatogram peak-
area
percentage, millimolar, etc.). One skilled in the art would readily understand
that
there are other ways to determine the percentage of glycopeptide or
glycopeptide
breakdown products, for example Vancomycin or Vancomycin breakdown products,
in solutions of the invention after a predetermined time period.
Stability of the present solutions can also be expressed in terms other than
the
percentage of glycopeptide antibiotic or glycopeptide antibiotic breakdown
products, for example Vancomycin remaining or of Vancomycin breakdown
products, in solution after a predetermined time point. Stability can also be
expressed in terms of concentration or absolute amount of either glycopeptide
antibiotic (for example as Vancomycin B) or of any glycopeptide antibiotic,
for
example Vancomycin, breakdown product or combination of breakdown products.
Stability can also be represented as the purity of the active ingredients in a
solution of the invention. For example, if the solution initially contains the
glycopeptide antibiotic in a certain purity, the stability of the solution
will be
reflected by a decrease in the chromatographic purity of the glycopeptide
antibiotic
over time. A stable solution would contain the glycopeptide antibiotic in a
specified
chromatographic purity after a predetermined time period. In Table 1, the
initial
chromatographic purity of Vancomycin is approximately 96% and decreases to
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
approximately 87% during storage for 4 weeks at 25 C in solutions that are not
stabilized.
5 Suitable techniques for measuring the concentration of glycopeptide
antibiotic,
for example Vancomycin (generally measured as Vancomycin B) or glycopeptide
antibiotic, for example Vancomycin, breakdown products in the present
solutions
are known in the art, and include HPLC and other liquid chromatographic
methods
such as is disclosed in the United States Pharmacopeia - National Formulary
for
10 Vancomycin Hydrochloride (USP 36 ¨ NF 31), the disclosure of which is
herein
incorporated by reference. A preferred method for measuring the concentration
of
glycopeptide antibiotics and glycopeptide antibiotic breakdown products, such
as
Vancomycin and/or Vancomycin breakdown products, is shown in the Examples
below and is disclosed in the European Pharmacopeia 8.0, pages 3525-3527, the
15 disclosure of which in incorporated herein by reference.
Stability of the present solutions can also be measured by testing the
activity of
the glycopeptide antibiotic in the solution at the end of a predetermined time
period.
For example, the ability of the solution to inhibit bacterial growth can be
measured
and can be compared, for example, to the activity of a portion of the solution
tested
at the beginning of the predetermined time period. Alternatively, the
glycopeptide
antibiotic activity of a solution of the invention after a predetermined time
period
can be compared to that of a freshly made, identical solution or a control
solution of
glycopeptide antibiotic. In a preferred embodiment, the present solutions
comprise
Vancomycin. Suitable methods for determining Vancomycin activity in solutions
of
the invention include tests for determining minimum inhibitory concentration
of
Vancomycin in a solution of the invention as against standard test organisms,
such
as Staphylococcus aureus. A preferred method for determining Vancomycin
activity
in the present solutions is shown in Example 5 below.
The present invention provides stable or stabilized glycopeptide antibiotic
solutions that can be transported, stored and used without special conditions
(i.e,
refrigeration) as formulated for up to two years from being produced. As used
herein, a stable or stabilized solution of the invention can be a solution
that is stable
or stabilized (as discussed above) in the liquid state for between about one
week and
24 months. For example, a stable or stabilized solution of the invention can
be a
solution which is stable or stabilized (as discussed above) in the liquid
state for at
least about one week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8
weeks, 9 weeks, 10 weeks, 11 weeks or 12 weeks. For example, a stable or
stabilized solution of the invention can be a solution which is stable or
stabilized (as
discussed above) in the liquid state for at least up to about 3, 4, 5, 6, 8,
10, 12, 14,
16, 18, 20, 21, 22, 23 or 24 months under normal conditions of shipping and
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
16
storage, i.e. at temperatures of about 25 degrees Celsius. In one embodiment,
solutions of the invention are stable or stabilized for about 17, 18, 21 or 24
months
at about 25 degrees Celsius.
The stable or stabilized solutions of the invention are suitable for
administration
to a subject at any time during their stability period (for example, for
between about
one week and 24 months). Suitable for administration to a subject means that
the
stable or stabilized solution of the invention contains sufficient
glycopeptide
antibiotic, for example Vancomycin, and is sufficiently free of impurities
(including
glycopeptide antibiotic breakdown products) that the solution will produce the
desired therapeutic effect on the subject. Thus, the invention provides a
method of
treating a bacterial infection in a subject, comprising administering a
solution of the
invention to a subject, so that a therapeutically effective amount of
glycopeptide
antibiotic is delivered. In a preferred embodiment, a therapeutically
effective
amount of Vancomycin is delivered.
As used herein, a "therapeutically effective amount of glycopeptide
antibiotic" is
an amount which is sufficient to treat a subject's bacterial infection. A
bacterial
infection is treated when one or more symptoms of that infection remain
substantially the same, are ameliorated to any degree, or prevented from
occurring.
Treatment of a bacterial infection also includes exhibition of bactericidal or
bacteriostatic effects. A skilled medical practitioner is able to assess
whether a
bacterial infection is being treated upon administration of solutions of the
invention.
The treatment method according to the invention also includes delivery of
glycopeptide antibiotic to a subject such that certain pharmacokinetic
parameters
are met. For example, solutions of the invention, if delivered by intravenous
infusion, can produce the pharmacokinetic parameters described in Table 2 of
Van
Bambeke, F (2006), Curr. Opin. Invest. Drugs 7(8): 740-749, the disclosure of
which is herein incorporated by reference. In a preferred embodiment,
solutions of
the invention comprising Vancomycin, if delivered by intravenous infusion, can
produce the pharmacokinetic parameters described in the Vancomycin HC1 for
Injection package insert from Hospira, incorporated herein by reference. Thus,
intravenous delivery of solutions of the invention to a subject can produce a
mean
plasma concentration of 63 micrograms/mL immediately after infusion of 1 gram
Vancomycin (15 mg/kg) over 60 minutes. Multiple dosing of 500 mg Vancomycin
infused over 30 minutes can produce a mean plasma concentration of about 49
microgram/mL at the completion of infusion, mean plasma concentrations of
about
19 microgram/mL two hours after infusion, and mean plasma concentrations of
about 10 microgram/mL six hours after infusion.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
17
It is understood that the solutions of the invention can be formulated and
delivered in any suitable manner, as is well-known in the art. For example,
the
present solutions can be administered parenterally; e.g., by intravenous
infusion.
The present solutions can also be administered enterally, for example orally.
Glycopeptide antibiotic compositions in liquid state according to the present
invention include any pharmaceutically acceptable concentration of
glycopeptide
antibiotic, for example Vancomycin. Further included is any concentration of
glycopeptide antibiotic which upon dilution with a suitable diluent will
provide a
pharmaceutically acceptable concentration. E.g the concentration of
glycopeptide
antibiotic, for example Vancomycin, in the solutions according to the present
invention include about 0.1-20% w/V, 0.5-20% w/V 3-15% w/V, 5-15% w/V, or 3-
10% w/V. The preferred concentration of glycopeptide antibiotic, for example
Vancomycin, in the solutions according to the present invention include about
0.5 -
15% w/V. Even more preferred concentration of glycopeptide antibiotic, for
example in the solutions according to the present invention include about 0.5-
10%
w/V. Also preferred are solutions comprising about 0.5% w/V, about 5% w/V or
about 10% w/V glycopeptide antibiotic, for example Vancomycin.
According to the present invention, the suitable molar ratio of an N-
acetylated-D-
amino acid to glycopeptide antibiotic, for example Vancomycin, is about 0.5:1
to
40:1. According to the present invention, a preferred molar ratio of an N-
acetylated-
D-amino acid to glycopeptide antibiotic, for example Vancomycin, is about 1:1
to
20:1. According to the present invention, a preferred molar ratio of an N-
acetylated-
D-amino acid to glycopeptide antibiotic, for example Vancomycin, is about 1:1
to
30:1
According to the present invention, the suitable molar ratio of N-acetyl-D-
Alanine to glycopeptide antibiotic, for example Vancomycin, is about 0.5:1 to
40:1.
According to the present invention, a preferred molar ratio of N-acetyl-D-
Alanine to
glycopeptide antibiotic, for example Vancomycin, is about 1:1 to 20:1.
According to
the present invention, a preferred molar ratio of N-acetyl-D-Alanine to
glycopeptide
antibiotic, for example Vancomycin, is about 1:1 to 30:1.
According to the present invention, the suitable molar ratio of N-acetyl-D-
Alanine to glycopeptide antibiotic, for example Vancomycin, is about 5:1 to
40:1
for a solution comprising about 0.5% w/V of glycopeptide antibiotic. According
to
the present invention, a preferred molar ratio of N-acetyl-D-Alanine to
glycopeptide
antibiotic, for example Vancomycin, is about 30:1 for a solution comprising
about
0.5% w/V glycopeptide antibiotic.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
18
According to the present invention, the suitable molar ratio of N-acetyl-D-
Alanine to glycopeptide antibiotic, for example Vancomycin, is about 0.1:1 to
10:1
for a solution comprising about 5% w/V glycopeptide antibiotic. According to
the
present invention, a preferred molar ratio of N-acetyl-D-Alanine to
glycopeptide
antibiotic, for example Vancomycin, is about 2:1 for a solution comprising
about
5% w/V glycopeptide antibiotic.
According to the present invention, the suitable molar ratio of N-acetyl-
Glycine
to glycopeptide antibiotic, for example Vancomycin, is about 0.5:1 to 40:1.
According to the present invention, a preferred molar ratio of N-acetyl-
Glycine to
glycopeptide antibiotic, for example Vancomycin, is about 1:1 to 30:1.
According to
the present invention, a preferred molar ratio of N-acetyl-Glycine to
glycopeptide
antibiotic, for example Vancomycin, is about 1:1 to 20:1.
According to the present invention, the suitable molar ratio of an amino acid
to
glycopeptide antibiotic, for example Vancomycin, is about 0.5:1 to 40:1.
According
to the present invention, a preferred molar ratio of an amino acid to
glycopeptide
antibiotic, for example Vancomycin, is about 1:1 to 30:1. According to the
present
invention, a preferred molar ratio of an amino acid to glycopeptide
antibiotic, for
example Vancomycin, is about 1:1 to 20:1.
As used herein, a "suitable molar ratio" is the molar ratio of an excipient to
glycopeptide antibiotic, for example Vancomycin, in the solutions of the
invention
which allows the formation of a stable or stabilized solution of the invention
as
defined herein, and includes the molar ratios described in the above
paragraphs.
The stable or stabilized glycopeptide antibiotic compositions according to the
present invention include optionally an amino acid. In a preferred embodiment,
the
stable or stabilized glycopeptide antibiotic compositions according to the
present
invention comprise Vancomycin and include optionally an amino acid.
The preferred amino acids include Alanine, Serine, Leucine, Valine, Lysine,
Arginine and Ornithine. The most preferred amino acids include D-Alanine, D-
Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Ornithine, D-Ornithine or L-
Arginine.
The amino acids can be added to the compositions in the form of
pharmaceutically acceptable salts. E.g. L-Lysine can be added to the
compositions
in the form of the chloride salt; L-Lysine hydrochloride. L-Lysine can also be
added
to the compositions in the form of an acetate salt; L-Lysine acetate.
The most preferred N-acetylated amino acid derivatives include N-acetyl-
Glycine
and N-acetyl-D-Alanine.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
19
Among the many formulations provided according to the present invention, the
following are also included:
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about
1:0.5-
1:20 having a pH of about 3-6 further comprising an amino acid.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:20 having a pH of about 3-6 further comprising an amino acid.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:30 having a pH of about 3-6 further comprising an amino acid.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:40 having a pH of about 3-6 further comprising an amino acid.
= Aqueous pharmaceutical compositions comprising 0.5-15% w/V glycopeptide
antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:20 having
a
pH of about 3-6 further comprising an amino acid selected from Serine,
Leucine,
Valine, Lysine, Arginine and Ornithine.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:30 having a pH of about 3-6 further comprising an amino acid selected from
Serine, Leucine, Valine, Lysine, Arginine and Ornithine.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:40 having a pH of 3-6 further comprising an amino acid selected from Serine,
Leucine, Valine, Lysine, Arginine and Ornithine.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:20 having a pH of about 3-6 further comprising an amino acid selected from D-
Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-
Ornithine.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:30 having a pH of about 3-6 further comprising an amino acid selected from D-
Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-
Ornithine.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/v
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:40 having a pH of about 3-6 further comprising an amino acid selected from D-
Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-
5 Ornithine.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:20 having a pH of about 3-6 further comprising an amino acid selected from D-
10 Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-
Ornithine or L-
Ornithine in a molar ratio to glycopeptide antibiotic of 1:1-20:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
15 1:20 having a pH of about 3-6 further comprising an amino acid
selected from D-
Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-
Ornithine in a molar ratio to glycopeptide antibiotic of about 1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
20 glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of
about 1:1-
1:30 having a pH of about 3-6 further comprising an amino acid selected from D-
Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-
Ornithine in a molar ratio to glycopeptide antibiotic of about 1:1-20:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:30 having a pH of about 3-6 further comprising an amino acid selected from D-
Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-
Ornithine in a molar ratio to glycopeptide antibiotic of about 1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:40 having a pH of about 3-6 further comprising an amino acid selected from D-
Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-
Ornithine in a molar ratio to glycopeptide antibiotic of about 1:1-20:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:40 having a pH of about 3-6 further comprising an amino acid selected from D-
Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-
Ornithine in a molar ratio to glycopeptide antibiotic of about 1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:40 having a pH of about 3-6 further comprising an amino acid selected from D-
Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-
Ornithine in a molar ratio to glycopeptide antibiotic of about 1:1-30:1;
further
comprising about 5-30% V/V of an pharmaceutically acceptable organic solvent.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
21
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:40 having a pH of about 3-6 further comprising an amino acid selected from D-
Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-
Ornithine in a molar ratio to glycopeptide antibiotic of about 1:1-30:1;
further
comprising about 5-50% V/V of an pharmaceutically acceptable organic solvent.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of about 1:1-
1:40 having a pH of about 3-6 further comprising an amino acid selected from D-
Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-
Ornithine in a molar ratio to glycopeptide antibiotic of 1:1-30:1; further
comprising about 10% v/v of ethanol.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in the molar ratio of 1:1-1:40
having a pH of about 3-6 further comprising an amino acid selected from D-
Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-
Ornithine in a molar ratio to glycopeptide antibiotic of about 1:1-30:1;
further
comprising about 5-50% v/v of polyethylene glycol.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in molar ratio about 1:1-1:20
having a pH of about 3-6 further comprising an amino acid selected from L-
Lysine, D-Lysine, L-Arginine, L-Ornithine or D-Ornithine in a molar ratio to
glycopeptide antibiotic of about 1:1-20:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in molar ratio about 1:1-1:30
having a pH of about 3-6 further comprising an amino acid selected from L-
Lysine, D-Lysine, L-Arginine, L-Ornithine or D-Ornithine in a molar ratio to
glycopeptide antibiotic of about 1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in molar ratio about 1:1-1:40
having a pH of about 3-6 further comprising an amino acid selected from L-
Lysine, D-Lysine, L-Arginine, L-Ornithine or D-Ornithine in a molar ratio to
glycopeptide antibiotic of about 1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in molar ratio about 1:1-1:30
having a pH of about 3-6 further comprising L-Lysine in a molar ratio to
glycopeptide antibiotic of about 1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in molar ratio about 1:1-1:40
having a pH of about 3-6 further comprising L-Lysine in a molar ratio to
glycopeptide antibiotic of about 1:1-30:1.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
22
= Aqueous pharmaceutical compositions comprising about 0.1-1% w/V
glycopeptide antibiotic and N-acetyl-D-Alanine in molar ratio about 1:5-1:40
having a pH of about 3-6 further comprising L-Lysine in a molar ratio to
glycopeptide antibiotic of about 1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5% w/V
glycopeptide
antibiotic and N-acetyl-D-Alanine in molar ratio about 1:30 having a pH of
about
4.5-6.5 further comprising L-Lysine in a molar ratio to glycopeptide
antibiotic of
about 1:20.
= Aqueous pharmaceutical compositions comprising about 0.5% w/V
glycopeptide
antibiotic and N-acetyl-D-Alanine in a molar ratio about 1:30 having a pH of
about 4-6 further comprising L-Lysine in a molar ratio to glycopeptide
antibiotic
of about 1:20.
= Aqueous pharmaceutical compositions comprising about 0.5% w/V
glycopeptide
antibiotic and N-acetyl-D-Alanine in a molar ratio about 1:30 having a pH of
about 4.5-5.5 further comprising L-Lysine in a molar ratio to glycopeptide
antibiotic of about 1:20.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and an N-modified-D-amino acid in the molar ratio of
about 1:1-1:20 having a pH of about 3-6 optionally further comprising an amino
acid.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and an N-modified-D-amino acid in the molar ratio of
about 1:1-1:30 having a pH of about 3-6 optionally further comprising an amino
acid.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and an N-modified-D-amino acid in the molar ratio of
about 1:1-1:40 having a pH of about 3-6 optionally further comprising an amino
acid.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
glycopeptide antibiotic and an N-modified-D-amino acid in the molar ratio of
about 1:1-1:40 having a pH of about 3-6 further comprising an amino acid.
= Compositions comprising about 0.5-15% w/V glycopeptide antibiotic and N-
acetyl-D-Alanine in the molar ratio of about 1:1-1:20 having a pH of about 3-6
further comprising an amino acid selected from D-Serine, D-Leucine, D-Valine,
L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine in a molar ratio to
glycopeptide antibiotic of about 1:1-20:1; further comprising about 10% V/V of
ethanol.
= Compositions comprising about 0.5-15% w/V glycopeptide antibiotic and N-
acetyl-D-Alanine in the molar ratio of about 1:1-1:30 having a pH of about 3-6
further comprising an amino acid selected from D-Serine, D-Leucine, D-Valine,
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
23
L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine in a molar ratio to
glycopeptide antibiotic of about 1:1-20:1; further comprising about 10% V/V of
ethanol.
= Compositions comprising about 0.5-15% w/V glycopeptide antibiotic and N-
acetyl-D-Alanine in the molar ratio of about 1:1-1:40 having a pH of about 3-6
further comprising an amino acid selected from D-Serine, D-Leucine, D-Valine,
L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine in a molar ratio to
glycopeptide antibiotic of about 1:1-30:1; further comprising about 10% V/V of
ethanol.
= Compositions comprising about 0.5-15% w/V glycopeptide antibiotic and N-
acetyl-D-Alanine in the molar ratio of about 1:1-1:20 further comprising an
amino acid.
= Compositions comprising about 0.5-15% w/V glycopeptide antibiotic and N-
acetyl-D-Alanine in the molar ratio of about 1:1-1:30 further comprising an
amino acid.
= Compositions comprising about 0.5-15% w/V glycopeptide antibiotic and N-
acetyl-D-Alanine in the molar ratio of about 1:1-1:40 further comprising an
amino acid.
= Compositions comprising about 0.5-15% w/V glycopeptide antibiotic and N-
acetyl-D-Alanine in the molar ratio of about 1:1-1:20 having a pH of about 3-6
further comprising an amino acid.
= Compositions comprising about 0.5-15% w/V glycopeptide antibiotic and N-
acetyl-D-Alanine in the molar ratio of about 1:1-1:30 having a pH of about 3-6
further comprising an amino acid.
= Compositions comprising about 0.5-15% w/V glycopeptide antibiotic and N-
acetyl-D-Alanine in the molar ratio of about 1:1-1:40 having a pH of about 3-6
further comprising an amino acid.
= Compositions comprising about 0.5-15% w/V glycopeptide antibiotic and N-
acetyl-D-Alanine in the molar ratio of about 1:1-1:40 having a pH of about 4-6
further comprising L-Lysine in the molar ratio of about 1:1-1:30 and further
about
50-60% V/V polyethylene glycol and water q.s.
= Compositions comprising about 0.5-15% w/V glycopeptide antibiotic and N-
acetyl-D-Alanine in the molar ratio of about 1:1-1:40 having a pH of about 5-6
further comprising L-Lysine in the molar ratio of about 1:1-1:30 and further
about
50-60% V/V PEG 400 or PEG 300 and water q.s.
= Compositions comprising about 5% w/V glycopeptide antibiotic and N-acetyl-
D-
Alanine in the molar ratio of about 1:2 having a pH of about 4-6 further
comprising L-Lysine in the molar ratio of about 1:2 and further about 55% V/V
PEG 400 and water q.s.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
24
= Compositions comprising about 5% w/V glycopeptide antibiotic and N-acetyl-
D-
Alanine in the molar ratio of about 1:2 having a pH of about 4.5-5.5 further
comprising L-Lysine in the molar ratio of about 1:2 and further about 55% V/V
PEG 400 and water q.s.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:0.5-1:20
having a pH of about 3-6 further comprising an amino acid.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:20 having
a pH of about 3-6 further comprising an amino acid.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:30 having
a pH of about 3-6 further comprising an amino acid.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:40 having
a pH of about 3-6 further comprising an amino acid.
= Aqueous pharmaceutical compositions comprising 0.5-15% w/V Vancomycin
and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:20 having a pH of
about
3-6 further comprising an amino acid selected from Serine, Leucine, Valine,
Lysine, Arginine and Ornithine.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:30 having
a pH of about 3-6 further comprising an amino acid selected from Serine,
Leucine, Valine, Lysine, Arginine and Ornithine.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:40 having
a pH of 3-6 further comprising an amino acid selected from Serine, Leucine,
Valine, Lysine, Arginine and Ornithine.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:20 having
a pH of about 3-6 further comprising an amino acid selected from D-Serine, D-
Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:30 having
a pH of about 3-6 further comprising an amino acid selected from D-Serine, D-
Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/v
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:40 having
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
a pH of about 3-6 further comprising an amino acid selected from D-Serine, D-
Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
5 Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:20
having
a pH of about 3-6 further comprising an amino acid selected from D-Serine, D-
Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine
in a molar ratio to Vancomycin of 1:1-20:1.
10 = Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:20 having
a pH of about 3-6 further comprising an amino acid selected from D-Serine, D-
Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine
in a molar ratio to Vancomycin of about 1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:30 having
a pH of about 3-6 further comprising an amino acid selected from D-Serine, D-
Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine
in a molar ratio to Vancomycin of about 1:1-20:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:30 having
a pH of about 3-6 further comprising an amino acid selected from D-Serine, D-
Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine
in a molar ratio to Vancomycin of about 1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:40 having
a pH of about 3-6 further comprising an amino acid selected from D-Serine, D-
Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine
in a molar ratio to Vancomycin of about 1:1-20:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:40 having
a pH of about 3-6 further comprising an amino acid selected from D-Serine, D-
Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine
in a molar ratio to Vancomycin of about 1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:40 having
a pH of about 3-6 further comprising an amino acid selected from D-Serine, D-
Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine
in a molar ratio to Vancomycin of about 1:1-30:1; further comprising about 5-
30% V/V of an pharmaceutically acceptable organic solvent.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:40 having
a pH of about 3-6 further comprising an amino acid selected from D-Serine, D-
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
26
Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine
in a molar ratio to Vancomycin of about 1:1-30:1; further comprising about 5-
50% V/V of an pharmaceutically acceptable organic solvent.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of about 1:1-1:40 having
a pH of about 3-6 further comprising an amino acid selected from D-Serine, D-
Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine
in a molar ratio to Vancomycin of 1:1-30:1; further comprising about 10% v/v
of
ethanol.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in the molar ratio of 1:1-1:40 having a pH
of about 3-6 further comprising an amino acid selected from D-Serine, D-
Leucine, D-Valine, L-Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine
in a molar ratio to Vancomycin of about 1:1-30:1; further comprising about 5-
50% v/v of polyethylene glycol.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in molar ratio about 1:1-1:20 having a pH
of about 3-6 further comprising an amino acid selected from L-Lysine, D-
Lysine,
L-Arginine, L-Ornithine or D-Ornithine in a molar ratio to Vancomycin of about
1:1-20:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in molar ratio about 1:1-1:30 having a pH
of about 3-6 further comprising an amino acid selected from L-Lysine, D-
Lysine,
L-Arginine, L-Ornithine or D-Ornithine in a molar ratio to Vancomycin of about
1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in molar ratio about 1:1-1:40 having a pH
of about 3-6 further comprising an amino acid selected from L-Lysine, D-
Lysine,
L-Arginine, L-Ornithine or D-Ornithine in a molar ratio to Vancomycin of about
1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in molar ratio about 1:1-1:30 having a pH
of about 3-6 further comprising L-Lysine in a molar ratio to Vancomycin of
about
1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and N-acetyl-D-Alanine in molar ratio about 1:1-1:40 having a pH
of about 3-6 further comprising L-Lysine in a molar ratio to Vancomycin of
about
1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.1-1% w/V
Vancomycin and N-acetyl-D-Alanine in molar ratio about 1:5-1:40 having a pH
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
27
of about 3-6 further comprising L-Lysine in a molar ratio to Vancomycin of
about
1:1-30:1.
= Aqueous pharmaceutical compositions comprising about 0.5% w/V Vancomycin
and N-acetyl-D-Alanine in molar ratio about 1:30 having a pH of about 4.5-6.5
further comprising L-Lysine in a molar ratio to Vancomycin of about 1:20.
= Aqueous pharmaceutical compositions comprising about 0.5% w/V Vancomycin
and N-acetyl-D-Alanine in a molar ratio about 1:30 having a pH of about 4-6
further comprising L-Lysine in a molar ratio to Vancomycin of about 1:20.
= Aqueous pharmaceutical compositions comprising about 0.5% w/V Vancomycin
and N-acetyl-D-Alanine in a molar ratio about 1:30 having a pH of about 4.5-
5.5
further comprising L-Lysine in a molar ratio to Vancomycin of about 1:20.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and an N-modified-D-amino acid in the molar ratio of about 1:1-
1:20 having a pH of about 3-6 optionally further comprising an amino acid.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and an N-modified-D-amino acid in the molar ratio of about 1:1-
1:30 having a pH of about 3-6 optionally further comprising an amino acid.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and an N-modified-D-amino acid in the molar ratio of about 1:1-
1:40 having a pH of about 3-6 optionally further comprising an amino acid.
= Aqueous pharmaceutical compositions comprising about 0.5-15% w/V
Vancomycin and an N-modified-D-amino acid in the molar ratio of about 1:1-
1:40 having a pH of about 3-6 further comprising an amino acid.
= Compositions comprising about 0.5-15% w/V Vancomycin and N-acetyl-D-
Alanine in the molar ratio of about 1:1-1:20 having a pH of about 3-6 further
comprising an amino acid selected from D-Serine, D-Leucine, D-Valine, L-
Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine in a molar ratio to
Vancomycin of about 1:1-20:1; further comprising about 10% V/V of ethanol.
= Compositions comprising about 0.5-15% w/V Vancomycin and N-acetyl-D-
Alanine in the molar ratio of about 1:1-1:30 having a pH of about 3-6 further
comprising an amino acid selected from D-Serine, D-Leucine, D-Valine, L-
Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine in a molar ratio to
Vancomycin of about 1:1-20:1; further comprising about 10% V/V of ethanol.
= Compositions comprising about 0.5-15% w/V Vancomycin and N-acetyl-D-
Alanine in the molar ratio of about 1:1-1:40 having a pH of about 3-6 further
comprising an amino acid selected from D-Serine, D-Leucine, D-Valine, L-
Lysine, D-Lysine, L-Arginine, D-Ornithine or L-Ornithine in a molar ratio to
Vancomycin of about 1:1-30:1; further comprising about 10% V/V of ethanol.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
28
= Compositions comprising about 0.5-15% w/V Vancomycin and N-acetyl-D-
Alanine in the molar ratio of about 1:1-1:20 further comprising an amino acid.
= Compositions comprising about 0.5-15% w/V Vancomycin and N-acetyl-D-
Alanine in the molar ratio of about 1:1-1:30 further comprising an amino acid.
= Compositions comprising about 0.5-15% w/V Vancomycin and N-acetyl-D-
Alanine in the molar ratio of about 1:1-1:40 further comprising an amino acid.
= Compositions comprising about 0.5-15% w/V Vancomycin and N-acetyl-D-
Alanine in the molar ratio of about 1:1-1:20 having a pH of about 3-6 further
comprising an amino acid.
= Compositions comprising about 0.5-15% w/V Vancomycin and N-acetyl-D-
Alanine in the molar ratio of about 1:1-1:30 having a pH of about 3-6 further
comprising an amino acid.
= Compositions comprising about 0.5-15% w/V Vancomycin and N-acetyl-D-
Alanine in the molar ratio of about 1:1-1:40 having a pH of about 3-6 further
comprising an amino acid.
= Compositions comprising about 0.5-15% w/V Vancomycin and N-acetyl-D-
Alanine in the molar ratio of about 1:1-1:40 having a pH of about 4-6 further
comprising L-Lysine in the molar ratio of about 1:1-1:30 and further about 50-
60% V/V polyethylene glycol and water q.s.
= Compositions comprising about 0.5-15% w/V Vancomycin and N-acetyl-D-
Alanine in the molar ratio of about 1:1-1:40 having a pH of about 5-6 further
comprising L-Lysine in the molar ratio of about 1:1-1:30 and further about 50-
60% V/V PEG 400 or PEG 300 and water q.s.
= Compositions comprising about 5% w/V Vancomycin and N-acetyl-D-Alanine in
the molar ratio of about 1:2 having a pH of about 4-6 further comprising L-
Lysine
in the molar ratio of about 1:2 and further about 55% V/V PEG 400 and water
q.s.
= Compositions comprising about 5% w/V Vancomycin and N-acetyl-D-Alanine in
the molar ratio of about 1:2 having a pH of about 4.5-5.5 further comprising L-
Lysine in the molar ratio of about 1:2 and further about 55% V/V PEG 400 and
water q.s.
The invention also provides methods of stabilizing glycopeptide antibiotic,
for example Vancomycin, in a pharmaceutical solution of the invention,
comprising
mixing N-acetyl-D-Alanine or N-acetyl Glycine and Vancomycin. The order in
which these components are mixed is not critical. Thus, N-acetyl-D-Alanine or
N-
acetyl Glycine can be added to a solution comprising glycopeptide antibiotic,
or
glycopeptide antibiotic can be added to a solution comprising N-acetyl-D-
Alanine
or N-acetyl-Glycine. In a preferred embodiment, N-acetyl-D-Alanine is added to
a
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
29
solution comprising glycopeptide antibiotic or glycopeptide antibiotic is
added to a
solution comprising N-acetyl-D-Alanine. The invention also provides methods of
manufacturing a stable aqueous glycopeptide antibiotic, for example
Vancomycin,
pharmaceutical solution comprising the steps of mixing glycopeptide antibiotic
and
an excipient selected from N-acetyl-D-Alanine or N-acetyl-Glycine. Again, the
order in which these components are mixed is not critical. In a preferred
embodiment, the components are mixed in the order Vancomycin base + diluted
HC1 in a stoichiometric amount + N-Acetyl-D-Alanine, as this results in a
complete
conversion of Vancomycin base to Vancomycin hydrochloride. Nonlimiting
exemplary methods to stabilize Vancomycin or manufacture solutions according
to
the invention are shown in the Examples below.
Solutions stabilized or manufactured according to methods of the invention can
be made suitable for use with human or animal subjects by techniques known in
the
art, for example by sterilizing the solution by any suitable means, and
packaging the
solutions in sealed containers from which the solution can later be dispensed
to the
subject.
The invention further provides kits comprising the solutions of the
inventions.
The kits can comprise one or more containers holding solutions of the
invention,
preferably ready to use in treatment of a bacterial infection in a subject.
However, it
is also contemplated that the solutions in the one or more containers can be
diluted
with a pharmaceutically acceptable diluent before administration to a subject.
The
kits can further comprise materials, one or more devices or one or more
apparatuses
for dispensing or delivering the solutions of the invention to a subject, or
for
diluting the present solutions. The kits may further comprise instructions for
the
storage and/or use of the solutions of the invention.
The invention is illustrated by the following non-limiting examples:
Examples
The stabilizing effect of different factors such as use of amino acids in
aqueous
Vancomycin compositions, Vancomycin concentration and pH of the aqueous
pharmaceutical composition, molar ratio of Vancomycin to amino acids and use
of
organic solvents (such as ethanol, PEG 300 and PEG 400) under standardized
stability testing conditions were evaluated.
General Techniques
All formulations presented in examples below were prepared with the starting
volume of ultrapure water equal to about 50% - 80% of the final batch volume.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
Presented aqueous Vancomycin compositions comprised between 0.5% ¨ 10%
(w/V) of Vancomycin.
Certain aqueous pharmaceutical compositions comprised a pH adjusting agent.
5 When required, pH was adjusted using diluted HC1 and/or NaOH solutions.
"Basic Vancomycin" formulations (5% and 10% Vancomycin, w/V) and
formulations without N-acetyl-D-Alanine or N-acetyl-Glycine are shown for
comparative purposes. All solutions were tested using validated HPLC methods
able
10 to quantify Vancomycin purity (Vancomycin B content) and the two main
degradation impurities DAMS and CDP1. The solutions were analyzed immediately
after preparation (start analysis), filled into vials, stoppered and stored
for 4 weeks
at 25 2 C/60 5% RH or 30 2 C and retested after a predetermined time period
expired.
The HPLC conditions used were those disclosed in the European Pharmacopeia
8.0, pages 3525-3527, employing acceptable variations to the conditions as
would
be understood by those skilled in the art for certain sample, using the
following
conditions:
Vancomycin B liquid chromatography (2.2.29). The solutions were used within 4
hours of preparation.
Test solution (a). Dissolved 10.0 mg of the substance to be examined in mobile
phase A and diluted to 5.0 mL with mobile phase A.
Test solution (b). Diluted 2.0 mL of test solution (a) to 50.0 mL with mobile
phase
A.
Test solution (c). Diluted 0.5 mL of test solution (b) to 20.0 mL with mobile
phase
A.
Reference solution. Dissolved the contents of a vial of Vancomycin
Hydrochloride
CRS in water R and diluted with the same solvent to obtain a solution
containing
0.5 mg/mL. Heated at 65 C for 24 h. Allowed to cool.
Column:
size: 1 = 0.25 m, 0= 4.6 mm
stationary phase: octadecylsilyl silica gel for chromatography R (5 pm).
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
31
Mobile phase:
Mobile phase A: to 4 mL of triethylamine R added 1996 mL of water R and
adjusted to pH 3.2 with phosphoric acid R; to 920 mL. of this solution was
added 10
mL. of tetrahydrofuran R and 70 mL of acetonitrile R;
Mobile phase B: to 4 mL of triethylamine R was added 1996 mL of water R and
adjusted to pH 3.2 with phosphoric acid R; to 700 mL of this solution was
added 10
mL. of tetrahydrofuran R and 290 mL of acetonitrile R;
Time Mobile phase A Mobile phase B
(min) (percent V/V) (percent V/V)
0-13 100 0
13-22 100 -> 0 0 -> 100
Flow rate: 1.0 mL/min.
Detection: spectrophotometer at 280 nm.
Injection: 20 [it.
System suitability:
resolution: minimum 5.0 between the 2 principal peaks in the chromatogram
obtained with the reference solution;
signal-to-noise ratio: minimum 5 for the principal peak in the chromatogram
obtained with test solution (c);
symmetry factor: maximum 1.6 for the peak due to Vancomycin in the
chromatogram obtained with test solution (b).
Calculated the percentage content of Vancomycin B hydrochloride using the
following expression:
(Abx100)/(Ab+(At/25) )
Ab = area of the peak due to Vancomycin B in the chromatogram obtained with
test
solution (b);
At = sum of the areas of the peaks due to impurities in the chromatogram
obtained
with test solution (a).
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
32
Related substances. Liquid chromatography (2.2.29) was performed as described
in
the test for Vancomycin B with the following modifications:
Injection: test solution (a), (b) and (c).
Calculated the percentage content of each impurity using then following
expression:
((Ai/25)x100)/(Ab+(At/25) )
Ai = area of the peak due to an impurity in the chromatogram obtained with
test
solution (a);
Ab = area of the peak due to Vancomycin B in the chromatogram obtained with
test
solution (b);
At = sum of the areas of the peaks due to impurities in the chromatogram
obtained
with test solution (a).
Example 1 ¨ Stabilization effect of amino acids:
Aqueous pharmaceutical compositions of Vancomycin base and Vancomycin
hydrochloride were prepared in predetermined concentrations and in certain
compositions (as shown below). Solution pH was further adjusted using diluted
HC1
solution or diluted NaOH solution. After Vancomycin and amino acids were added
into the solution in the molar ratios specified in Table 1 below, the solution
was
mixed until the substances were dissolved.
Purity (%)
DAMS (%) CDP1 (%)
Vancomycin
Composition Molar ratio pH 4 weeks
at 4 weeks at 4 weeks at 0
conc. (%) START
START START n.)
25 C
25 C 25 C
1-,
-C
Vancomycin HC1 5 / 3.13 96.3 86.6
0.6 4.5 0.2 6.0 cA
;
Vancomycin HC1 10 / 3.05 96.2 87.5
0.7 4.3 0.2 5.2
1-,
.6.
N-acetyl-D-Alanine + Vancomycin base
2:1 3.06 96.5 94.9 0.6 1.2 0.2 1.1
un
+ 4M HC1#
N-acetyl-D-Alanine + Vancomycin base 5 2:1 3.22 96.5
95.3 0.6 1.1 0.2 0.9
L-Serine + Vancomycin HC1 + 4M HC1# 10 2:1 2.98 96.2
87.6 0.6 4.1 0.2 5.2
D-Serine + Vancomycin HC1 + 4M HC1# 10 2:1 3.00 96.2
89.6 0.6 3.4 0.2 4.3
N-acetyl-D-Alanine + D-Serine +
5 2:2:1 3.31 96.5 95.3
0.6 0.8 0.2 0.8
Vancomycin base
D-Leucine + Vancomycin HC1+ 4M
1:1 3.02 96.2 89.2 0.6 3.4 0.2 4.3
HC1#
P
N-acetyl-D-Alanine + D-Leucine +
0
5 2:2:1 3.40 96.5 95.6
0.6 0.8 0.2 0.7 1.,
Vancomycin base
L-Lysine + Vancomycin HC1 + 4M HC1# 10 2:1 3.03 96.5
87.6 0.7 3.9 0.1 4.9
0.
1.,
L-Lysine + D-Alanine + Vancomycin
0
10 2:2:1 2.98 96.5 93.7
0.7 1.5 0.1 1.7 1-
..J
'
HC1+ 4M HC1#
0
0.
1
L-Lysine + L-Alanine + Vancomycin
1-
10 2:2:1 3.00 96.1
91.7(*) 0.6 3.1(*) 0.2 2.1(*) "
HC1+ 4M HC1#
L-Lysine + Glycine + Vancomycin HC1
10 2:2:1 3.00 96.2
91.3(*) 0.6 3.2(*) 0.2 2.5(*)
+ 4M HC1#
N-acetyl-D-Alanine + L-Lysine +
5 2:2:1 3.05 96.5 94.8
0.6 1.0 0.2 1.1
Vancomycin HC1+ 4M HC1#
N-acetyl-D-Alanine + L-Lysine +
5 2:2:1 4.41 96.4 96.1
0.6 0.7 0.2 0.5
Vancomycin HC1
IV
N-acetyl-Glycine + L-Lysine +
n
10 2:2:1 2.99 96.1 94.3
0.6 1.3 0.3 1.5
Vancomycin HC1+ 4M HC1#
M
IV
L-Arginine + Vancomycin HC1+ 4M
n.)
10 2:1 3.00 96.4
92.0(*) 0.6 3.1(*) 0.3 2.1(*) =
HC1#
un
-C
N-acetyl-D-Alanine + L-Arginine +
;
5 2:2:1 4.05 96.5 95.9
0.6 0.7 0.2 0.6
un
Vancomycin HC1
1-,
oe
0
r..)
o
Purity (%)
DAMS (%) CDP1 (%)
cA
Vancomycin
Composition Molar ratio pH 4 weeks
at 4 weeks at 4 weeks at CB;
conc. (%) START
START START --.1
1-,
25 C
25 C 25 C .6.
Vancomycin HC1+ D-Lysine + N-acetyl-
un
1:2:2 5.45 96.2 95.8 0.6 0.6 0.2 0.6
D-Alanine + 0.4M NaOH#
Vancomycin HC1 + D-Ornithine + N-
5 1:2:2 5.48 96.2 95.8
0.6 0.6 0.2 0.7
acetyl-D-Alanine + 2M/0.4M NaOH#
Vancomycin HC1+ L-Ornithine + N-
5 1:2:2 5.49 96.2 95.8
0.6 0.6 0.2 0.7
acetyl-D-Alanine + 2M/0.4M NaOH #
Vancomycin HC1 + L-Lysine
monohydrate + N-acetyl-D-Alanine + 5 1:2:2 5.54 96.3
95.9 0.6 0.7 0.2 0.7
0.5M NaOH#
P
0
Vancomycin HC1 + L-Lysine
"
monohydrochloride + N-acetyl-D- 5 1:2:2 5.46 96.4 95.8
0.6 0.6 0.2 0.6
u,
1.,
Alanine + 2M/0.5M NaOH #
0.
IV
0
Vancomycin HC1 + L-Lysine acetate +
1-
5 1:2:2 5.48 96.3 95.6
0.6 0.7 0.3 0.9 ..J
1
N-acetyl-D-Alanine + 2M/0.5M NaOH #
Oh
,
#Used as pH adjusting agent
,
N,
(*) 2 weeks data (at 25 2 060 5% RH)
IV
n
m
,-o
t..,
=
u,
7:-:--,
--.1
u,
,4z
oe
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
Example 2 ¨ Stabilization effect of Vancomycin concentration and pH of the
preparation:
Aqueous pharmaceutical compositions of Vancomycin were prepared in varying
5 concentrations, and in certain formulations pH was further adjusted using
diluted
HC1 solution and/or diluted NaOH solution. After Vancomycin and amino acids
were added into the solution in the molar ratios specified in Table 2 below,
the
solution was mixed until substances were dissolved.
0
t,..)
o
Table 2
cA
a-,
-....,
.6.
Purity (%)
DAMS (%) CDP1 (%) vo
un
Vancomycin
Composition Molar
ratio pH
conc. (%) START 4
weeks at 25 C START 4 weeks at 25 C START 4 weeks at 25 C
Vancomycin HC1 5 / 3.13
96.3 86.6 0.6 4.5 0.2 6.0
Vancomycin HC1 10 / 3.05
96.2 87.5 0.7 4.3 0.2 5.2
N-acetyl-D-Alanine + L-Lysine + Vancomycin HC1+ 2M HC1# 0.5 2:2:1
3.96 96.5 92.2 0.6 1.7 0.2 3.3
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine + 0.4M Na01-0 2.5 1:2:2
5.57 96.4 95.1 0.6 0.6 0.3 1.5
P
N-acetyl-D-Alanine + L-Lysine + Vancomycin HC1+ 1M NaOH# 5 2:2:1
5.45 96.5 96.1 0.6 0.6 0.2 0.6 0
1.)
0
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine + 0.4M Na0H5 3 1:2:2
5.52 96.4 95.6 0.6 0.7 0.2 0.9
u)
1.)
0.
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine + 0.4M Na0H44 4 1:2:2
5.47 96.4 95.8 0.6 0.6 0.2 0.7 1.)
0
1-
N-acetyl-D-Alanine + L-Lysine + Vancomycin HC1 + 4M HC1# 5 2:2:1
3.05 96.5 94.8 0.6 1.0 0.2 1.1 ...J
1
0
N-acetyl-D-Alanine + Vancomycin base + 4M HC1# 5 2:1 3.06
96.5 94.9 0.6 1.2 0.2 1.1 Oh
1
I-'
IV
Vancomycin HC1+ L-Lysine + N-acetyl-D-Alanine 5 1:2:2 4.08
96.5 96.0 0.6 0.7 0.2 0.6
N-acetyl-D-Alanine + L-Lysine + Vancomycin HC1 5 2:2:1 4.41
96.4 96.1 0.6 0.7 0.2 0.5
N-acetyl-D-Alanine + L-Lysine + Vancomycin HC1 + 4M HC1# + 1M Na0F11/ 5
2:2:1 4.43 96.5 96.1 0.6 0.7 0.2 0.5
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine + 0.4M NaOH* 5 1:2:2
4.97 96.3 95.8 0.6 0.7 0.2 0.6
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine + 0.4M Na0F1* 5 1:2:2
5.56 96.3 95.8 0.6 0.6 0.2 0.7
Vancomycin HC1+ N-acetyl-D-Alanine + 1M NaOH# 5 1:2 7.89
96.3 93.9 0.6 0.4 0.3 2.7
IV
Itsed as pH adjusting agent
n
1-i
m
Iv
t,..)
o
,-,
u,
a-,
-....,
u,
oe
CA 02964524 2017-04-12
WO 2016/071495
PCT/EP2015/075918
37
Example 3 ¨ Stabilization effect of molar ratio of Vancomycin and amino acids
present in the aqueous pharmaceutical compositions.
Aqueous pharmaceutical compositions of Vancomycin hydrochloride were prepared
in varying concentrations, and in certain formulations pH was further adjusted
using
diluted HC1 solution and/or diluted NaOH solution. After Vancomycin and amino
acids
were added into the solution in the molar ratios specified in Table 3 below,
the solution
was mixed until substances were dissolved.
Table 3
0
Purity (%)
DAMS (%) CDP1 (%)
4
4 4
Vancomycin
Composition Molar ratio
conc. (%) START
START START pH weeks 4 weeks weeks 4 weeks weeks 4 weeks
at
at 30 C at at 30 C at at 30 C
25 C
25 C 25 C
Vancomycin HC1 5
3.13 96.3 86.6 85.6 (*) 0.6 4.5 5.1 (*) 0.2 6.0
6.2 (*)
Vancomycin HC1 10
3.05 96.2 87.5 87.2 (*) 0.7 4.3 4.8 (*) 0.2 5.2
5.1 (*)
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine 5
1:1.5:1.5 4.04 96.3 95.8 95.0 0.6 0.8 0.9 0.2 0.7
1.4
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine 5 1:2:2
4.08 96.5 96.0 95.6 0.6 0.7 0.8 0.2 0.6 1.0
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine 5 1:1.5:3
3.31 96.3 95.7 95.0 0.6 0.7 0.8 0.2 0.6 1.3
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine 5 1:1:1.5
3.32 96.3 95.1 93.9 0.6 1.0 1.1 0.2 1.1 2.2
cn
N-acetyl-D-Alanine + L-Lysine + Vancomycin HC1 + 4M HC1# 10
1:1:1 2.98 96.1 95.2 93.6 0.6 1.0 1.3 0.3 1.0
2.2 oe
0
N-acetyl-D-Alanine + L-Lysine + Vancomycin HC1 + 1M NaOH 5
2:2:1 5.45 96.5 96.1 95.7 0.6 0.6 0.6 0.2 0.6
1.0
0
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine + 0.4M NaOH# 5
1:3:3 5.44 96.3 96.1 95.9 0.6 0.6 0.6 0.2 0.5
0.7
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine + 2M/0.4M HC1# 5
1:3:3 3.19 96.3 95.5 94.5 0.6 0.7 0.8 0.2 0.7
1.5
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine + 2M/0.4M HC1# 5
1:3:2 5.55 96.2 95.9 95.4 0.6 0.6 0.6 0.2 0.7
1.2
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine + 2M HC1 5
1:3:2 3.22 96.3 95.1 93.8 0.6 0.9 1.0 0.2 1.0
1.9
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine + 0.4M NaOH#1:10:10 5.52 96.4
95.4 94.6 0.6 0.6 0.6 0.2 1.0 1.7
(in 0.9% NaC1)
oe
Purity (%)
DAMS (%) CDP1 (%)
4
4 4
Vancomycin
Composition Molar ratio pH
conc. (%)
START weeks 4 weeks START weeks 4 weeks START weeks 4 weeks
CB;
at
at 30 C at at 30 C at at 30 C
25 C 25 C 25 C
0.5
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine + 0.4M NaOH# 1:20:20
5.53 96.4 95.6 95.3 0.6 0.6 0.6 0.2 0.7 1.1
(in 0.9% NaC1)
0.5
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine + 0.5M HC1# 1:30:30 5.54
96.4 96.0 95.7 0.6 0.6 0.6 0.3 0.6 0.9
(in 0.9% NaC1)
0.5
Vancomycin HC1 + L-Lysine + N-acetyl-D-Alanine + 2M/0.4M NaOH#
1:20:30 5.50 96.4 95.9 95.6 0.6 0.6 0.6 0.3 0.5
0.9
(in 0.9% NaC1)
o
0.5
Vancomycin HC1 + L-Lysine HC1 + N-acetyl-D-Alanine + 2M/1M/0.4M NaOH#
1:20:20 5.51 96.3 95.8 95.2 0.6 0.6 0.6 0.2 0.7 1.3
c.")
(in 0.9% NaC1)
0.5
0
Vancomycin HC1 + L-Lysine HC1 + N-acetyl-D-Alanine + 2M NaOH#
1:20:30 5.49 96.4 96.0 na 0.5 0.6 na 0.3 0.5 na
(in 0.9% NaC1)
na - not analyzed
#Used as pH adjusting agent
(*) only 2 weeks data available (at 30 2 075 5% RH)
,4z
oe
CA 02964524 2017-04-12
WO 2016/071495
PCT/EP2015/075918
Example 4 ¨ Stabilization effect of organic solvents.
Pharmaceutical compositions of Vancomycin hydrochloride containing an organic
solvent (ethanol, PEG 300 or PEG 400) were prepared in varying concentrations,
and in
certain formulations pH was further adjusted using diluted HC1 solution and/or
diluted
NaOH solution. After Vancomycin and amino acids were added into the solution
in the
molar ratio specified in Table 4 below, the solution was mixed until
substances were
dissolved.
Table 4
Purity (%)
DAMS (%) CDP1 (%) 0
n.)
Vancomycin Molar
Used o
Composition pH 4 weeks
4 weeks 4 weeks
conc. (%) ratio solvent START
START START cA
at 25 C
at 25 C at 25 C
--.1
1-,
N-acetyl-D-Alanine + Ultrapure
.6.
2:1 3.06 96.5 94.9 0.6 1.2 0.2 1.1
un
Vancomycin base + 4M HC1# water
N-acetyl-D-Alanine + 9.6% Et0H
Vancomycin base + in 9.6% in
5 2:1 2.99 96.5 94.9
0.6 1.0 0.2 0.9
ethanol (V/V) in ultrapure ultrapure
water + 4M HC1# water
Ultrapure
Vancomycin HC1 10 / 3.05 96.2 87.5
0.7 4.3 0.2 5.2
water
40% PEG
Vancomycin HC1 in 40% PEG 300 + 60%
P
/ 2.88 96.3 90.9 0.6 3.4 0.2 1.5
0
1.,
300 (V/V) in ultrapure water ultrapure
4=,
.
water
u,
1.,
0.
40% PEG
0
Vancomycin HC1 in 40% PEG 400 + 60%
1-
..J
'
10 / 2.74 96.5 91.3
0.7 3.3 0.1 1.5 0
400 (V/V) in ultrapure water ultrapure
Oh
I
I-'
water
Vancomycin HC1+ L-Lysine +
Ultrapure
N-acetyl-D-Alanine + 0.4M 5 1:2:2 5.47 96.4 95.8
0.6 0.6 0.2 0.8
water
Na01-1#
Vancomycin HC1+ L-Lysine + 20% PEG
N-acetyl-D-Alanine in 20% 300 + 80%
5 1:2:2 5.06 96.2 96.2
0.6 0.6 0.2 0.4
PEG 300 (V/V) in ultrapure ultrapure
water water
IV
n
Vancomycin HC1+ L-Lysine + 20% PEG
N-acetyl-D-Alanine in 20% 400+ 80%
M
5 1:2:2 4.91 96.2 96.1
0.6 0.7 0.3 0.4 IV
n.)
PEG 400 (V/V) in ultrapure ultrapure
o
1-,
water water
un
-C;
Vancomycin HC1+ L-Lysine Ultrapure
5 1:2:2 5.46 96.4 95.8
0.6 0.6 0.2 0.6 un
HC1+ N-acetyl-D-Alanine + water
oe
Purity (%)
DAMS (%) CDP1 (%)
Vancomycin Molar Used
Composition pH 4 weeks
4 weeks 4 weeks 0
conc. (%) ratio solvent START
START START n.)
at 25 C
at 25 C at 25 C o
1-,
cA
2/0.5M NaOH#
CB;
--.1
Vancomycin HC1 + L-Lysine 55% PEG
.6.
HC1 + N-acetyl-D-Alanine + 400 + 45%
un
1:2:2 5.51 96.3 96.3 0.6 0.5 0.3 0.3
5/2/0.5M NaOH# in 55% PEG ultrapure
400 (V/V) in ultrapure water water
Vancomycin HC1 + L-Lysine 10% PEG
HC1 + N-acetyl-D-Alanine + 400 + 90%
5 1:2:2 5.48 96.3 95.8
0.6 0.6 0.3 0.5
2/0.5M NaOH# in 10% PEG ultrapure
400 (V/V) in ultrapure water water
Vancomycin HC1 + L-Lysine
HC1 + N-acetyl-D-Alanine + 0.5 1:20:20 5.51 0.9% NaC1
96.3 95.8 0.6 0.6 0.2 0.7 P
2/110.4M NaOH#
0
1.,
4=,
.
Vancomycin HC1 + L-Lysine
5.5% PEG
u,
1.,
HC1 + N-acetyl-D-Alanine +
0.
0.5 1:20:20 5.49 400 + 94.5 96.3 96.0 0.6
0.6 0.2 0.5
0.1/0.5/1/2M NaOH# in 5.5%
1-
0.9% NaC1
..J
1
PEG 400 (V/V) in 0.9% NaC1
0
Oh
I
Vancomycin HC1 + L-Lysine 5.5% PEG
1-
1.,
HC1 + N-acetyl-D-Alanine + 400 +
0.5 1:20:20 5.50 96.4 96.0 0.5 0.5
0.3 0.4
0.5/2M NaOH# in 5.5% PEG 94.5% 5%
400 (V/V) in 5% dextrose dextrose
Vancomycin HC1 + L-Lysine
HC1 + N-acetyl-D-Alanine + 0.5 1:20:30 5.49 0.9% NaC1
96.4 96.0 0.5 0.6 0.3 0.5
2M NaOH#
Vancomycin HC1 + L-Lysine 5.5% PEG
IV
HC1 + N-acetyl-D-Alanine + 400 +
n
0.5 1:20:30 5.43 96.4 96.0 0.6 0.6
0.2 0.5
2/0.5M NaOH# in 5.5% PEG 94.5%
M
IV
400 (V/V) in 0.9% NaC1 0.9% NaC1
t..)
o
1-,
#Used as pH adjusting agent
un
CB;
--.1
un
1-,
oe
CA 02964524 2017-04-12
WO 2016/071495
PCT/EP2015/075918
43
Example 5
ANTIBACTERIAL SUSCEPTIBILITY TESTING
Testing was performed using broth dilution method according to Clinical and
Laboratory Standards Institute (CLSI) guidelines M100-S23/S24; M07-A9, the
disclosure of which is herein incorporated by reference.
The antibiotic activity of eight aqueous pharmaceutical compositions was
determined
and compared to the activity of the injectable reference finished product,
Vancocin,
manufactured by Flynn Pharma Ltd. Antibiotic activity was determined against
quality
control strains: Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC
29212 and Streptococcus pnemoniae ATCC 49619. These solutions were stored at
25
degrees Celsius for the time periods indicated, and the results are shown in
Table 5
below.
A further 13 solutions were stored under the same conditions as those shown in
Table 5 for the time periods indicated, and were tested using the same CLSI
protocol
against two different Vancomycin solution standards and an amoxicillin
standard. The
results are shown in Table 6 below. Table 7 shows referent minimum inhibitory
concentration (MIC) ranges for evaluation of Vancomycin solution activity
against
tested quality control strains according to the CLSI protocol. As shown in
Tables 5 and
6, all tested solutions of the invention demonstrated antibiotic activity
comparable to
the control reference solution, and the MICs measured were all within the CLSI
referent
MIC ranges, demonstrating that the tested solutions were stable.
Table 5
MIC ( g/mL)
0
Test period in Vancomycin
Staphylococcus Enterococcus Streptococcus n.)
Test article Composition Molar ratio pH
o
days conc. (%)
aureus faecalis pnemoniae
cA
-a
Vancocin
;
--..1
1¨,
(reference
.6.
/ / / / /
1 2 0.25
lyophilized
un
product)
10% 96% ethanol + D-Alanine
1 85 + L-Lysine + Vancomycin HC1 2:2:1 10
3.02 1 4 0.25
+ 4M HC1#
N-acetyl-D-Alanine + L-Lysine
2 58 2:2:1 5 3.05
1 4 0.25
+ Vancomycin HC1 + 4M HC1#
N-acetyl-D-Alanine +
3 58 2:1 5 3.06
1 4 0.25
Vancomycin+ 4M HC1#
P
0
N-acetyl-D-Alanine + L-Lysine
4 25 2:2:1 5 4.29
0.5 4 0.25 '
4=,
.
+ Vancomycin HC1
.6. 0.
u,
1.,
N-acetyl-D-Alanine + L-Lysine
Ø
1.,
10 + Vancomycin HC1 + 1M 2:2:1 5 4.43 1
2 0.25 0
1-.
..J
1
NaOH
0
Ø
1
N-acetyl-D-Alanine + L-Lysine
1.,
6 10 + Vancomycin HC1 + 1M 2:2:1 5 5.45
1 4 0.25
NaOH
N-acetyl-D-Alanine + L-Lysine
7 9 + Vancomycin HC1 (in 0.9% 2:2:1 5
5.11 1 4 0.125
NaC1)
Vancomycin HC1 + L-Lysine +
8 6 1:2:2 5 4.08
1 4 0.125
N-acetyl-D-Alanine
IV
n
#Used as pH adjusting agent
M
IV
n.)
o
1¨,
un
-1
--.1
un
1¨,
oe
Table 6
Test
Staphylococcus Enterococcus Streptococcus 0
Vancomycin
r..)
Test article period in Composition Molar ratio pH
aureus faecalis pneumoniae o
conc. (%)
days
MIC (pg/mL) cA
-C;
1
0.5 0.06 --.1
1¨,
Amoxicillin USP
.6.
CLSI range
CLSI range CLSI range (0.03-
standard
un
(0.5-2)
(0.5-2) 0.125)
1
2 0.125
Vancomycin USP
CLSI range
CLSI range CLSI range
standard
(0.5-2)
(1-4) (0.125-0.5)
Vancocin
(reference
1 2 0.125
lyophilized
product)
P
Vancomycin HC1 + L-Lysine
0
1.,
HC1 + N-acetyl-D-Alanine +
.6. g
1 195 1:2:2 5 5.51
1 4 0.25
5/2/0.5M NaOH# in 55% PEG
u,
1.,
Ø
400 (V/V) in ultrapure water
0
1-.
Vancomycin HC1 + L-Lysine
..J
1
0
HC1 + N-acetyl-D-Alanine +
Ø
,
2 154 1:2:2 5 5.48
1 4 0.25
1.,
2/0.5M NaOH# in 10% PEG
400 (V/V) in ultrapure water
Vancomycin HC1 + L-Lysine
HC1 + N-acetyl-D-Alanine +
3 150 1:20:30 0.5 5.43
1 2 0.25
2/0.5M NaOH# in 5.5% PEG
400 (V/V) in0.9% NaC1
Vancomycin HC1 + L-Lysine
4 128 HC1 + N-acetyl-D-Alanine + 1:2:2 5
5.04 1 2 0.125 00
n
4/2M NaOH#
M
Vancomycin HC1 + L-Lysine
00
r..)
5 126 HC1 + N-acetyl-D-Alanine + 1:2:2 5
5.05 1 2 0.25
1¨,
un
4M NaOH#
-a;
--..1
Vancomycin HC1 + L-Lysine
un
6 79 1:2:2 5 5.30
1 2 0.25
HC1 + N-acetyl-D-Alanine +
oe
2M NaOH# in 18% PEG 400
(V/V) in ultrapure water
Vancomycin HC1 + L-Lysine
0
r..)
HC1 + N-acetyl-D-Alanine +
o
7 79 1:2:2 5 5.31
1 2 0.25
2M NaOH# in 30% PEG 400
CB;
(V/V) in ultrapure water
--.1
1¨,
.6.
Vancomycin HC1 + L-Lysine
un
HC1 + N-acetyl-D-Alanine +
8 781:2:2 5 5.14
1 2 0.125
2M NaOH# in 40% PEG 400
(V/V) in ultrapure water
Vancomycin HC1 + L-Lysine
9 70 HC1 + N-acetyl-D-Alanine + 1:20:30 0.5
5.03 1 2 0.125
2M NaOH# in 0.9% NaC1
Vancomycin HC1 + L-Lysine
HC1 + N-acetyl-D-Alanine +
44 1:20:30 0.5 5,05 1 4
0.25 P
2M NaOH# in 1.8% PEG 400
0
1.,
(V/V) in 0.9% NaC1
.
4=,
.
Vancomycin HC1 + L-Lysine
u,
1.,
Ø
11 160 HC1 + N-acetyl-D-Alanine + 1:20:30 0.5
5,49 1 2 0.25
0
2M NaOH# in 0.9% NaC1
..J
1
0
Vancomycin HC1 + L-Lysine
Ø
1
1-.
12 155 HC1 + N-acetyl-D-Alanine + 1:2:2 5
5,43 1 2 0.25 "
4/2M NaOH#
Vancomycin HC1 + L-Lysine
13 120 HC1 + N-acetyl-D-Alanine + 1:2:2 5
5,03 1 2 0.25
4/2M NaOH#
#Used as pH adjusting agent
IV
n
m
,-o
t..,
u,
7:-:--,
--.1
u,
,4z
oe
CA 02964524 2017-04-12
WO 2016/071495
PCT/EP2015/075918
47
Table 7
Referent MIC ranges (pg/mL)
QC strains Vancomycin
Staphylococcus aureus ATCC 29213 0.5-2
Enterococcus faecalis ATCC 29212 1-4
Streptococcus pnemoniae ATCC 49619 0.125-0.5
Example 6 ¨ Lack of stabilization of solutions containing Vancomycin and
peptides.
Solutions containing N-acetylated di- and tri-peptides in place of N-acetyl-
amino
acids were made. It was found that the pH of the formulations made with the N-
acetylated di- and tri-peptides could not be raised much above about pH 3,
since the
solutions started to appear hazy already at that pH value. Also, a solution
containing N-
acetyl-D-Alanine-D-Alanine and L-Lysine could not be made with Vancomycin
concentrations above about 0.2%, as it was observed that the solutions became
hazy as
the Vancomycin concentrations approached about 0.5%. Moreover, the low pH
values
necessary to maintain the solubility of Vancomycin in solutions containing N-
acetylated
di- and tri-peptides in place of N-acetyl-amino acids would cause rapid
degradation of
Vancomycin. Thus, these solutions were not considered stable or suitable for
use as a
pharmaceutical solution in a clinical setting. The results of this experiment
are
presented in Table 8 below.
The solutions were made by dissolving either N-acetyl-D-Alanine-D-Alanine or
Di-
acetyl-L-Lysine-D-Alanine-D-Alanine in water or 0.9% sodium chloride. In one
formulation, L-Lysine was then added. Vancomycin was then added, and in some
formulations the pH was adjusted using diluted hydrochloric acid to around pH
3.
Where Vancomycin HC1 salt was used, no pH adjustment was done. For the
formulation
containing L-Lysine, the formulation was intended to have 0.5% w/V Vancomycin
concentration, but after adjusting the pH to around 2.5 the solution was still
hazy. This
solution was then further diluted in order to make it less hazy, and
concentration of
0.2% w/V Vancomycin was obtained. Concentration of Vancomycin B, DAMS and
CDP1 were measured by HPLC as described above in the Examples: General
Techniques. Solutions were stored in glass vials and kept at 25 degrees
Celsius for four
weeks, except for the solution containing Di-acetyl-L-Lysine-D-Alanine-D-
Alanine +
Vancomycin HC1 + 4M HC1, for which only two-weeks stability data was
available.
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
48
Table 8
Vancomycin
Composition Molar ratio pH
conc. (%)
Vancomycin HC1 5 / 3.13
Vancomycin HC1 10 / 3.05
N-acetyl-D-Alanine-D-Alanine
0.5 1:1 2.95
+ Vancomycin HC1 + 4M HC1#
N-acetyl-D-Alanine-D-Alanine
0.5 1:1 2.67
+ Vancomycin HC1
N-acetyl-D-Alanine-D-Alanine
+ L-Lysine + Vancomycin HC1 0.2 1:1:1 2.50
+ 4M HC1# in 0.9% NaC1
Di-acetyl-L-Lysine-D-
Alanine-D-Alanine +
Vancomycin HC1 + 4M HC1# 0.5 1:1 2.95
in 0.9% NaC1
#Used as pH adjusting agent
Example 7 ¨ Stable Vancomycin solutions.
Aqueous pharmaceutical compositions of Vancomycin were prepared and tested as
described in Examples 1-3 above, and the results are given in Table 9. As
shown in
Table 9, the solutions of the invention were stable for 3 and 6 months under
the
conditions tested. These results, in particular the data for Vancomycin
Purity, DAMS
and CDP1 after 3 and 6 months at 25 degrees Celsius, can be extrapolated to
indicate
that the solutions are stable or stabilized for up to about 21 to >24 months.
0
t,..)
o
Table 9
c7,
a-,
-....,
Purity (%)
DAMS (%) CDP1 (%) Calculated shelf life .6.
uo
Vanco.
according to
Composition Molar ratio pH 6 months at 6 months at
6 months at
conc. (%) START START
START Vancomycin purity/
25 C
25 C 25 C
months
Vancomycin HC1 + L-Lysine HC1
+ N-acetyl-D-Alanine + 4/2M 5 1:2:2 5.03 96.2 93.9 0.6
0.5 0.3 2.7 22
NaOH#
Vancomycin HC1 + L-Lysine HC1
+ N-acetyl-D-Alanine + 5/2/0.5M
1:2:2 5.51 96.3 95.6 0.6 0.4 0.3 0.5
> 24
NaOH# in SS% PEG 400 (V/V) in
P
ultrapure water
0
s,
g
Purity (%)
DAMS (%) CDP1 (%) Calculated shelf life
Vanco.
according to "
Composition Molar ratio pH 3 months at 3 months at
3 months at 0
1-
conc. (%) START START
START Vancomycin purity/ ..J
'
25 C
25 C 25 C 0
months
0.
I
I-'
Vancomycin HC1 + L-Lysine HC1
"
+ N-acetyl-D-Alanine + 2M
5 1:2:2 5.30 96.2 95.4 0.6
0.4 0.3 0.9 > 24
NaOH* in 18% PEG 400 (V/V) in
ultrapure water
Vancomycin HC1 + L-Lysine HC1
+ N-acetyl-D-Alanine + 2M 0.5 1:20:30 5.49 96.4 95.2 0.5
0.6 0.3 1.2 21
NaOH# in 0.9%NaC1
Vancomycin HC1 + L-Lysine HC1
IV
+ N-acetyl-D-Alanine + 2M
0.5 1:20:30 5.06 96.2 95.0 0.6
0.5 0.3 1.2 21 n
NaOH# in 1.8% PEG 400 (V/V)
1-3
in 0.9% NaC1
M
IV
ts.)
#Used as pH adjusting agent
o
1-,
5
vi
a-,
-....,
u,
oe
CA 02964524 2017-04-12
WO 2016/071495 PCT/EP2015/075918
Example 8 ¨ Stable glycopeptide antibiotic solutions.
Aqueous pharmaceutical compositions of Teicoplanin, Telavancin, Dalbavancin
5 and Oritavancin are prepared and tested as described in Examples 1-3 and
7 above.
It is expected that the solutions are stable for 3 and 6 months at 25 degrees
Celsius,
and that this can be extrapolated to indicate that the solutions are stable or
stabilized
for up to about 24 months.
